A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100242
Author(s):  
K. Klinghammer ◽  
J. Fayette ◽  
A. Kawecki ◽  
A. Dietz ◽  
P. Schafhausen ◽  
...  
2017 ◽  
Vol 22 (7) ◽  
pp. 782 ◽  
Author(s):  
Marco Siano ◽  
Francesca Molinari ◽  
Vittoria Martin ◽  
Nicolas Mach ◽  
Martin Früh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document